Skip to content
ApprovedFDA approvedStrong evidence

Istradefylline

Add-on Parkinson's medicine that reduces symptoms returning as levodopa wears off; not approved in the EU.

DopaminergicFocusDopaminergicFocusnoo.affects.adenosineDopaminenoo.affects.wakefulness

Pharmacology

ClassDopaminergic · Focus
Primary targetSelective adenosine A2A receptor antagonist
Targets2 receptor targets
Half-life~80 hours (long-acting, hence morning dosing to avoid sleep disruption)
OnsetOnce-daily dosing; clinical effect stabilizes over weeks
EvidenceStrong evidence
Affected systemsnoo.affects.adenosineDopaminenoo.affects.wakefulness

Contents

DETAILED OVERVIEW

What is Istradefylline?

Istradefylline (brand name Nourianz) is a prescription Parkinson's medicine given as an add-on to levodopa for people whose main medicine wears off too early and symptoms return. It was approved in the United States in 2019 and earlier in Japan; it has not been approved in the European Union.

It does not stimulate dopamine receptors. Instead, in the part of the brain that controls movement, it blocks one of the receptors for adenosine, a substance that puts a brake on dopamine's action. In several placebo-controlled trials this reduced the total time spent in bad periods. It can cause dizziness, headache, nausea and constipation; it can increase involuntary movements, cause hallucinations in older or susceptible patients and, rarely, impulse-control problems (such as gambling), and it can worsen symptoms in people with a history of psychosis. It is to be avoided in pregnancy because it caused developmental harm in animal studies. It is used only under medical supervision.

Mechanism

Selective adenosine A2A antagonist

Half-life

~80 hours (once daily, morning)

Legal status

FDA-approved prescription drug (2019)

Receptor profile

  • Adenosine A2A receptorStrong
  • Striatal dopamine D2 pathway (indirect)Moderate

Safety

Side effects, stop signs, contraindications

Side effects · 6

  • Worsening of dyskinesia (involuntary movements), especially when combined with levodopa
  • Dizziness, headache
  • Nausea and constipation
  • Insomnia (hence morning dosing is advised)
  • Hallucinations and other psychiatric symptoms, mainly in elderly or susceptible patients
  • Impulse-control disorders (e.g. gambling) rarely, as with dopaminergic treatments in general

Contraindications · 5

  • Pregnancy: showed developmental toxicity in animal studies, avoid
  • Severe hepatic impairment (Child-Pugh C): not recommended because clearance is reduced
  • History of psychosis or hallucinations: symptoms may worsen
  • Concomitant strong CYP3A4 inhibitors (dose must be halved) and strong CYP3A4 inducers should be avoided
  • Heavy smoking (over 20 cigarettes/day) markedly lowers blood levels; a higher dose may be needed

Related Nootropics

Same therapeutic category

Studies

Related research and clinical findings

FAQ

FAQ

Istradefylline is an officially FDA-approved medication used in Parkinson's disease as an add-on to levodopa, specifically for the periods when the main medication wears off and symptoms return (so-called OFF episodes). Its key feature is that it doesn't target the dopamine system directly but blocks a different brain signaling pathway, reducing bad-symptom time without triggering troublesome extra movements. It's taken once daily in the morning, and its effectiveness is backed by multiple clinical trials.

Telegram

Have a question about Istradefylline?

Reach out to us on Telegram for a personalized stack. We'll be happy to help.

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

Structure & chemistry

TypeDopaminergic
FormulaC20H24N4O4
UpdatedOctober 13, 2026
MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA
Updated: October 13, 2026

The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.